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Abstract
Background: Streptococcus suis serotype 2 (SS2) is a zoonotic agent that causes death and disease
in both humans and swine. A better understanding of SS2-host molecular interactions is crucial for
understanding SS2 pathogenesis and immunology. Conventional genetic and biochemical
approaches used to study SS2 virulence factors are unable to take into account the complex and
dynamic environmental stimuli associated with the infection process. In this study, in vivo-induced
antigen technology (IVIAT), an immunoscreening technique, was used to identify the immunogenic
bacterial proteins that are induced or upregulated in vivo during SS2 infection.
Results: Convalescent-phase sera from pigs infected with SS2 were pooled, adsorbed against in
vitro antigens, and used to screen SS2 genomic expression libraries. Upon analysis of the identified
proteins, we were able to assign a putative function to 40 of the 48 proteins. These included
proteins implicated in cell envelope structure, regulation, molecule synthesis, substance and energy
metabolism, transport, translation, and those with unknown functions. The in vivo-induced changes
in the expression of 10 of these 40 genes were measured using real-time reverse transcription
(RT)-PCR, revealing that the expression of 6 of the 10 genes was upregulated in the in vivo
condition. The strain distribution of these 10 genes was analyzed by PCR, and they were found in
the most virulent SS2 strains. In addition, protein sequence alignments of the newly identified
proteins demonstrate that three are putative virulence-associated proteins.
Conclusion: Collectively, our results suggest that these in vivo-induced or upregulated genes may
contribute to SS2 disease development. We hypothesize that the identification of factors
specifically induced or upregulated during SS2 infection will aid in our understanding of SS2
pathogenesis and may contribute to the control SS2 outbreaks. In addition, the proteins identified
using IVIAT may be useful potential vaccine candidates or virulence markers.
Background
Streptococcus suis (S. suis) infections have been considered
a major problem in the swine industry worldwide, partic-
ularly over the past 20 years. S. suis is a gram-positive, fac-
ultatively anaerobic coccus, and 35 serotypes (1-34 and 1/
2) have been described based on their capsular antigens.
Among these, serotype 2 (SS2) is the causative agent of
many different syndromes worldwide, including meningi-
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tis, septicemia, arthritis, and pneumonia in humans,
swine, and other animals [1]. In addition, SS2 is widely
recognized as an important zoonotic agent that afflicts
people in close contact with infected pigs or pork-derived
products [2,3]. Two recent large-scale outbreaks of human
streptococcal toxic shock syndrome (STSS) caused by SS2
in China in 1998 and in 2005 have increased public
health concerns worldwide. Notably, a major outbreak of
SS2 infection emerged in the summer of 2005 in Sichuan
Province, China. A total of 215 cases of human S. suis
infection were reported, and the outbreak resulted in 38
deaths and massive economic losses [4,5].
Little is known about the virulence factors of SS2. To date,
only a few SS2 virulence associated factors have been
identified and characterized; these include the capsular
polysaccharide (CPS) [1], suilysin (SLY) [6], muramidase-
released protein (MRP) [7], extracellular protein factor
(EF) [8], adhesin [9], cell wall-associated and extracellular
proteins [10], fibronectin- and fibrinogen-binding pro-
tein (FBP) [11], a serum opacity factor [12], and the
arginine deiminase system [13,14].
An understanding of SS2-host molecular interactions is
crucial for understanding SS2 pathogenesis and immu-
nology. Conventional genetic and biochemical
approaches used to study SS2 virulence factors are unable
to take into account in the complex and dynamic environ-
mental stimuli associated with the infection process.
Recently, several technologies, including in vivo expres-
sion technology (IVET), differential fluorescence induc-
tion (DFI), signature-tagged mutagenesis (STM),
transcriptional and proteomic profiling, and in vivo-
induced antigen technology (IVIAT) have been developed
to identify the pathogen genes expressed during the infec-
tion process [15,16].
IVIAT is a method that allows for the direct identification
of microbial proteins expressed at sufficient levels during
host infection to be immunogenic. A schematic of the
IVIAT procedure was described by Rollins et al [16]. The
advantage of IVIAT is that it enables the identification of
antigens expressed specifically during infection, but not
during growth in standard laboratory media. It was spec-
ulated that the genes and gene pathways identified by
IVIAT may play a role in virulence or pathogenesis during
bacterial infection [17,18]. IVIAT has been successfully
used to identify arrays of in vivo induced proteins in Sal-
monella enterica serovar Typhi [19], Escherichia coli O157
[18], Group A Streptococcus  (GAS) [17], Vibrio cholerae
[20], and others, and these proteins have been shown to
contribute to the pathogenesis or virulence of the infect-
ing organisms. When IVIAT was applied to E. coli O157, it
identified 223 O157 proteins expressed during human
infection. Among these, four proteins--intimin-γ (an
adhesin), QseA (a quorum-sensing transcriptional regula-
tor), TagA (a lipoprotein), and MsbB2 (an acyltrans-
ferase)--had been previously identified as virulence-
related proteins [18].
To identify SS2 proteins that are immunogenic and
expressed uniquely during SS2 infection, we applied the
newly developed and modified IVIAT method. Briefly, we
screened a library of SS2 proteins expressed in E. coli to
identify clones that were immunoreactive with convales-
cent-phase sera, which had been previously fully adsorbed
against  in vitro-grown SS2 and E. coli organisms. The
adsorption process eliminates antibodies reactive with in
vitro-expressed antigens and allows for the identification
of clones expressing protein antigens that are upregulated
during swine infection. Specifically, we hypothesized that
by using IVIAT, we could identify proteins that play a role
in the SS2-specific host-bacterium interactions unique to
SS2 infection in pigs. In this study, we identified 48 puta-
tive in vivo-induced (IVI) proteins, which included pro-
teins associated with bacterial cell wall structure,
metabolism, regulation, molecule synthesis, substance
transport and others. Of these, 10 genes were selected for
analysis by real-time PCR to confirm their in vivo upregu-
lation. Six genes were shown to be upregulated in vivo.
These results suggest that these newly identified genes
may contribute to SS2 pathogenesis.
Results
Sera selection and adsorption
IVIAT depends on the presence of antibodies directed
against pathogen antigens expressed in vivo, so the selec-
tion of convalescent sera for use in IVIAT must be carefully
considered. In this study, sera were selected that had an
antibody titer of at least 10,000. All eight convalescent-
phase sera, which were collected from recovered pigs as
described in the materials and methods, had antibody tit-
ers above 12,800. These eight pooled convalescent-phase
sera were mixed at equal volumes to create a sera cocktail
for IVIAT, in order to best balance individual immune var-
iability with the effects of dilution.
The adsorption efficiency was determined by examining
the immunoreactivity of the serum aliquots from the
pooled swine convalescent-phase sera after each adsorp-
tion step with whole cells and cell lysates of in vitro-grown
ZY05719. As shown in Figure 1, the immunoreactivity of
the pooled sera with in vitro-grown SS2 progressively
decreased with each round of adsorption; the decrease in
immunoreactivity was particularly noticeable after the
first adsorption step.
The immunoreactivity of the adsorbed pooled convales-
cent sera against in vitro-derived SS2 proteins was further
assessed with dot-ELISA using the individually purifiedBMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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proteins MRP, EF, and GAPDH, which are reportedly
expressed on the cell surface (Figure 2). Dot-ELISA results
showed that unadsorbed sera strongly reacted with MRP,
EF, and GAPDH (Figure 2A). However, when the sera had
been completely adsorbed with in vitro antigens, there
were no spots on the NC membrane (Figure 2B). These
results further validated that antibodies specific to in vitro
antigens had been fully removed from the convalescent-
phase sera set.
Use of adsorbed convalescent-phase sera to probe a 
genomic DNA expression library of the SS2 isolate 
ZY05719
To provide tenfold coverage of a SS2 genome (2 × 106 bp),
a plasmid library containing inserts whose average size is
2 kb would contain about 5.7 × 104 independent recom-
binants. The SS2 genomic library, prepared from strain
ZY05719 isolated from a Sichuan SS2 outbreak (Table 1),
in E. coli DH5α consisted of approximately 6 × 104 clones
for each expression vector (pET30 a, b, and c). These three
libraries were used for IVIAT selection with the adsorbed
convalescent sera. During the primary screening, 300 of
the most intensely immunoreactive clones were selected.
Following rigorous selection, 60 clones that continuously
showed a strong positive reaction with the adsorbed con-
valescent-phase sera antibodies were identified. Their
immunoreactivity was confirmed by an additional screen-
ing, in which these clones were compared with clones
bearing the vectors alone without any inserts present. The
positive clones were picked out and then cultured in
broth. The presence of a cloned DNA insert in all 60
clones was confirmed by PCR analysis and sequencing.
Categorization of the IVI proteins according to the actual 
or putative functions of the genes identified by IVIAT
The sequencing results showed that most of the immuno-
reactive clones contained only a portion of the coding
sequence of the relevant protein, and that these 60 clones
encoded 48 different proteins. The difference in the
number of positive clones and proteins is due to several
clones encoding the same protein. For instance, clones 6,
34, and 73 encoded the protein ysirk1. The nucleotide/
protein sequence data of the 48 in vivo-induced (IVI) pro-
teins were deposited in the NCBI GenBank database http:/
/www.ncbi.nlm.nih.gov, and the accession numbers that
were assigned to these sequences are listed in Table 2.
By evaluating previously published studies of Streptococcus
species and performing sequence alignments, we were
able to assign a functional classification to 40 of the 48
proteins identified by IVIAT. Since the SS2 genomes have
not been completely annotated, the genes identified by
IVIAT were named after their homolog in other bacteria,
when possible. When an IVI gene was unnamed, it was
assigned an annotation number http://www.sanger.ac.uk/
Projects/Microbes. These unnamed genes did not demon-
strate good homology with the SS2 P1/7 genome deter-
mined by the Sanger Institute http://www.sanger.ac.uk/
Projects/Microbes. Therefore, these genes were annotated
http://www.ncbi.nlm.nih.gov. Table 2 shows the 48 IVI
proteins encoded by these 60 clones that were categorized
according to the actual or putative functions of the open
reading frames (ORFs) identified by IVIAT. The IVI pro-
teins were grouped into eight categories: cell envelope,
regulatory, molecule synthesis, substance and energy
metabolism, transport, translation, others, and those with
unknown functions.
Among these 48 newly identified IVI proteins, we found
three proteins previously reported to have putative roles
in Streptococcus virulence. (i) Protein YSIRK1, when per-
forming protein-protein BLAST with the newly identified
IVI proteins against the NCBI database, we found that the
Enzyme immunoassay reactivities of sera with lysates of an in  vitro-grown SS2 strain after each step in sequential adsorp- tion Figure 1
Enzyme immunoassay reactivities of sera with 
lysates of an in vitro-grown SS2 strain after each step 
in sequential adsorption. Optical density values (OD450) 
were corrected for background and for dilution during 
adsorption. Swine convalescent sera cocktail sets were 
sequentially adsorbed with SS2 whole cells, cell lysates, and E. 
coli whole cells and cell lysates. Following sufficient adsorp-
tion with all these antigens, sera were considered to have 
been completely adsorbed. (A) ELISA plates coated with 
whole SS2 cells. (B) ELISA plates coated with SS2 cell lysates. 
The results are expressed as means of absorbance values, 
and error bars represent the standard errors of the means.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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protein encoded by ysirk1 is a potential virulence protein.
Its sequence indicates that it is a subtilisin-like serine pro-
tease homologous to surface-associated subtilisin-like ser-
ine protease PrtA of Streptococcus pneumoniae.
Interestingly, PrtA was also identified by screening a
genomic expression library from Streptococcus pneumoniae
using a convalescent-phase serum. Bethe and colleagues
reported that PrtA is a highly conserved virulence factor of
Streptococcus pneumoniae, and might be a promising candi-
date for a protein-based vaccine [21]. (ii) Autolysin, the
autolysin encoded by cwh  is also a reported virulence-
associated factor in SS2 [22]. Most bacteria possess several
autolysins that are able to degrade their cell walls, and are
implicated in various biological functions including cell
separation, cell wall turnover, restructuring of cell walls,
and bacterial autolysis. In addition, certain autolysins
have also been reported to contribute to the pathogenicity
of gram-positive bacteria. For example, an intact autolytic
function is required for the full virulence of Streptococcus
pneumoniae [23]. (iii) protein TRAG, TRAG is a compo-
nent of the type IV secretion system (T4SS), a virulence-
associated pathway of SS2 [22]. The bacterial T4SS, which
is widely distributed among the gram-negative and -posi-
tive bacteria and is ancestrally related to bacterial conjuga-
tion machines (which mediate protein and gene transfer),
contributes to pathogenicity [24].
Analysis of the in vivo gene expression profiles
Strain ZY05719 was selected for real-time PCR analysis
because it is one of the strains isolated from the 2005 SS2
outbreak in China; ZY05719 was also used for construct-
ing the genomic library. Of the 48 putative IVI genes, 10
(ss-1616, trag, nlpa, srt, cwh, hprk, ysirk, ss-1955, sdh, ss-
1298) were selected for further analysis of gene expression
by real-time PCR. We selected these genes based on their
putative functions, such as involvement in cell structure,
metabolism, regulation, and transport, in order to maxi-
mize the variety of genes chosen for further analysis. The
in vitro expression of these 10 putative IVI genes was
observed in early lag phase, log phase, late log phase, and
stationary phase of growth, with the highest level of
expression occurring at late log phase (data not shown).
Before comparing the expression of these 10 putative IVI
genes under the in vitro condition, they were first tested
under in vivo conditions (expression after challenge with
bacterial cells via intravenous inoculation measured at 12,
24, and 36 h pi). All of the putative IVI genes were
expressed in vivo under the conditions tested (data not
shown). With the exception of ysirk and ss-1955, which
were expressed at 12 h pi but not at 24 and 36 h pi, and ss-
1298, which was expressed until 36 h, the remaining 7 IVI
genes were expressed at 12, 24 and 36 h post-inoculation
in vivo. The aim of this study was to identify the genes
whose expressions are upregulated in vivo; therefore, we
determined the in vivo gene expression relative to the
highest level of expression in vitro. Of the 10 analyzed
genes, six genes, namely, ss-1616, trag, nlpa, hprk, sdh, and
ss-1298, were upregulated in vivo relative to the highest
level of expression of the corresponding gene in vitro (Fig-
ure 3).
Location of the IVI genes on the SS2 chromosome
To learn about location of the 48 IVI genes on the SS2
chromosome, we used BLAST to identify them in the S.
suis  strain P1/7 genomic sequence (genomic sequence
data were generated by the S. suis strain P1/7 Sequencing
Dot-ELISA results of reactivities of pooled unadsorbed (A) and adsorbed (B) swine convalescent sera against the three previ- ously reported SS2 virulence-associated proteins MRP, EF, and GAPDH Figure 2
Dot-ELISA results of reactivities of pooled unadsorbed (A) and adsorbed (B) swine convalescent sera against 
the three previously reported SS2 virulence-associated proteins MRP, EF, and GAPDH. BSA was used as a nega-
tive control.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Group at the Sanger Institute, and can be obtained from
ftp://ftp.sanger.ac.uk/pub/pathogens/ss/. Thirty-eight IVI
genes were located (data not shown). Four genes (trag,
exc-b, lac, and ppc) did not have high homology with P1/
7, but demonstrated homology with strains S. suis 89/
1591, 98HAH33, and 05ZYH33. The remaining six genes
could not be located because their sequences were short
and did not show high homology with any other
sequence in the database.
Pathogenicity islands (PAIs) are clusters of genes that may
contribute to virulence in pathogens, sometimes by
responding to environmental signals [25,26]. Wei et al.
(2006) predicted eight possible SS2 pathogenicity islands
based on a systematic analysis of the SS2 strain P1/7
genomic sequence [27]. In this study, five IVI genes (sdh,
srt, ss-1955, ss-1829, and ss-802) were found to be distrib-
uted in four pathogenicity islands (Figure 4) when located
on the SS2 chromosome.
Strain distribution of IVI genes
To determine whether the newly identified IVI genes are
common among SS2 isolates, we examined their distribu-
tion in SS2 isolates with different backgrounds, including
those isolated at different times and from different regions
and sources. PCR was employed to analyze the distribu-
tion of 10 IVI genes in Chinese strains (N = 23). Twenty-
three SS2 strains isolated from different regions of China
in different years were analyzed, and PCR results showed
that the distribution ratio of these IVI genes were as fol-
lows: ss-1616 (22/23, 95.7%), trag (23/23, 100%), nlpa
(22/23, 95.7%), srt (22/23, 95.7%), cwh (23/23, 100%),
hprk (23/23, 100%), ysirk (23/23, 100%), ss-1955 (23/23,
100%), sdh (23/23, 100%), ss-1298 (20/23, 87%) (details
not shown). The genomic sequences of SS2 strains P1/7,
89/1591, 98HAH33, 05ZYH33 were collected from
Sanger or the NCBI data library. The distribution of the 10
IVI genes in these strains was determined by nucleotide
sequence alignment (Table 3). With the exception of gene
trag, which was not found in strain P1/7, the nine remain-
ing IVI genes were found in all four of the above strains
(P1/7, 89/1591, 98HAH33, and 05ZYH33).
Discussion
S. suis infection is a major cause of sudden death of pigs,
and is also increasingly becoming a human health con-
cern due to its zoonotic transmission capabilities.
Attempts to control the infection have been hampered by
our lack of knowledge about SS2 pathogenicity. The iden-
tification and characterization of putative virulence fac-
tors and other infection-related proteins will aid in the
prevention and control of SS2 disease. IVIAT provides a
"snapshot" of protein expression during infection, allow-
ing us a glimpse into the possible mechanisms by which
this pathogen might counter host defenses and adapt and
establish itself within the host to cause disease [18]. In the
present study, we used the newly developed IVIAT
method to select in vivo-induced proteins.
Convalescent-phase sera collected from pigs naturally
infected with SS2 are ideal for IVIAT [16]. However, for
multiple reasons, it is not easy to acquire convalescent-
phase sera from SS2 natural infection. First, epidemiolog-
ical studies have found that SS2 outbreaks are usually
infrequent and only affect a small number of pigs, which
can lead to underdiagnosis or misdiagnosis. Second, pigs
infected with SS2 do not always show obvious clinical
symptoms, and may become carriers without showing
clinical signs. Finally, based on its polysaccharide capsular
antigens, at least 35 serotypes of S. suis exist. Isolates
belonging to other serotypes (such as 1, 1/2, 3, 4, 5, 7, 8
and 9) have also been associated with disease in pigs
[28,29]. Common antigens had been found to be shared
between SS2 and these other serotypes (unpublished data
from our lab). To reduce these possible interferences, we
used pigs with clear backgrounds as animal models, and
Table 1: Bacterial strains and plasmids used in this study
Strains or plasmids Serotype, Genotype and/or phenotype Reference/source
Strains
HA9801 serotype 2;cps2J+, mrp+, ef+, sly+, gapdh+, gdh+, orf2+ Jiangsu outbreak SS2 isolate, 1998, China
ZY05719 serotype 2; cps2J+, mrp+, ef+, sly+, gapdh+, gdh+, orf2+ Sichuan outbreak SS2 isolate, 2005, China
T15 serotype 2; cps2J+, mrp-, ef- The Netherlands
Plasmids
pET30(abc) Expression vectors allowing cloning of fragments in each of three reading 
frames; Kanr
Novagen
pMRP pET30(a) with partial mrp gene amplified from strain ZY05719, and cloned into 
EcoRI and XhoI sites, in vector, Kanr
This work
pEF pET30(a) with partial ef gene amplified from strain ZY05719, and cloned into 
EcoRI and XhoI sites, in vector, Kanr
This work
pGAPDH pET32(a) with partial gapdh gene amplified from strain ZY05719, and cloned 
into BamHI and SalI sites, in vector, Ampr
Previous work
Kanr, kanamycin-resistant; Ampr, ampicillin-resistant.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Table 2: Proteins encoded by IVIAT selected clones






ysirk1 YSIRK Gram-positive signal peptide cell wall EF127690
ysirk2 YSIRK Gram-positive signal peptide cell wall EF127720
ss-1616 hypothetical protein SsuiDRAFT 0718 cell wall EF127691
cwh Cell wall hydrolase/autolysin, peptidoglycan 
catabolism
cell wall EF127695
trag TRAG protein, essential for DNA transfer in 
bacterial conjugation
Membrane EF127701
srt sortase-like protein/Sortase family Cytoplasmic EF127708
nlpa NLPA lipoprotein Cytoplasmic EF127718
Regulation lac LacI:Periplasmic binding protein/LacI 
transcriptional Regulator
EF127711
hprk HPr(Ser) kinase, two-component signal 
transduction system/two-component sensor 
activity/regulates carbohydrate
Cytoplasmic EF127733
flps FlpS, regulation in arginine deiminase system Cytoplasmic EF127749
Molecule synthesis ss-896 Tagatose-6-phosphate kinase/pfkB family 
carbohydrate kinase
Cytoplasmic EF127693
ss-1611 Aspartate kinase/Amino acid kinase family Cytoplasmic EF127726
ss-1759 Amino acid biosynthesis/glutamate-cysteine ligase 
activity
Cytoplasmic
pol1 DNA polymerase I Cytoplasmic EF127735
cpn60 60 kDa chaperonin (Protein Cpn60) (groEL 
protein)/TCP-1/cpn60 chaperonin family
Cytoplasmic EF127737
prpn Primosomal protein n Cytoplasmic EF127740
pol3 DNA polymerase III, epsilon subunit:DNA 
polymerase III, alpha subunit, Gram-positive type
Cytoplasmic EF127741
EF127751
Substance and energy 
metabolism
gh3 Glycoside hydrolase, family 3, N-terminal/Tim 
barrel glycosyl hydrolase superfamily. 
carbohydrate metabolism/hydrolase activity, 
hydrolyzing O-glycosyl compounds
Cytoplasmic EF127713




Methyltransferase superfamily, Central 
intermediary metabolism
unknown EF127722
ss-862 Uracil DNA glycosylase/Uracil DNA glycosylase 
superfamily
Cytoplasmic EF127729
ss-802 ATPase Cytoplasmic Membrane EF127747
ss-1766 protein metabolism/ATP-dependent Clp protease, 
ATP-binding subunit
Cytoplasmic EF127719
ss-607 ABC transporter Cytoplasmic Membrane EF127697
sdh L-serine dehydratase, alpha subunit Cytoplasmic Membrane EF127704
ss-1617 Fructokinase/Actin-like ATPase Superfamily unknown EF127707
ppc Phosphoenolpyruvate carboxylase EF127727
ss-1305 ABC transporter Cytoplasmic Membrane EF127736
Transport ss-1955 conserved hypothetical protein, transport and 
binding
unknown EF127692
ss-273 ABC transporter, transport and binding/coupled 
to transmembrane movement of substances
Cytoplasmic Membrane EF127694
ss-1298 ABC transporter Cytoplasmic Membrane EF127714
ss-1829 peptidase, S54 (rhomboid) family protein/
Rhomboid family
Cytoplasmic Membrane EF127742
ss-403 PTS system sorbose subfamily IIB component cytoplasmic EF127754
Translation exc-b Excinuclease ABC, B subunit Cytoplasmic EF127698
EF127700
ss-887 O-acetylhomoserine sulfhydrylase/PLP dependent 
aminotransferase superfamily
Cytoplasmic EF127706
ss-349 possible product: hypothetical protein SMU_684 Cytoplasmic EF127738
ss-1935 Ribosomal protein S4, bacterial and organelle 
form
Cytoplasmic EF127739BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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convalescent sera were prepared following artificial infec-
tion.
Until recently, the exact mechanism of SS2 transmission
(from pig to human or between pigs) was still poorly
understood, but was thought to involve aerosol transmis-
sion or other pathways [28-30]. However, some hypothe-
ses about the critical stages of the infection, such as
bacterial invasion from the mucosal surfaces to the blood-
stream, survival of the bacteria in blood, and invasion
from blood into the central nervous system have been pre-
sented [28]. Regardless of the mechanism of SS2 invasion,
circulation in the blood plays an important role during
SS2 disease development. In addition, S. suis is an agent of
zoonosis, afflicting people in close contact with infected
pigs or pork-derived products. The organisms probably
gain entry via small wounds or through inhalation
[4,10,29]. Furthermore, transmission between pigs in
herds through cutaneous wounds has been suggested
[29]. In light of these considerations, intravenous and
intramuscular inoculations were employed to assay the
expression of SS2 in vivo, and to try to mimic natural infec-
tion (such as the middle or late stage of the infection).
In this study, we used real-time PCR to analyze the induc-
tion of the expression of IVI genes under different envi-
ronmental conditions. Real-time PCR results
demonstrated that the expression of six of the 10 selected
genes was upregulated under in vivo conditions. The
upregulation time points for these six genes were 12, 24,
and 36 h for ss-1616 and trag, 24 h for hprk and sdh, and
36 h for nlpa and ss-1298. This upregulated expression
suggests that these genes may play a significant role during
the course of SS2 infection (middle, late, or whole stage of
infection). The expression profiles of the other four genes
(ysirk, srt, cwh, and ss-1955) showed that they were not
obviously upregulated under the in vivo condition (Figure
3). There are two possible explanations for this result.
First, since we measured the in vivo gene expression at 12,
24, and 36 h pi, it is possible that we missed the time
when the levels of expression of these genes were high rel-
ative to the expression of the same gene in vitro. For
instance, they may play roles in the rapid replication of
SS2 during an early stage of infection. Second, the mRNA
concentration might not reflect the amount of protein or
antigen produced if these antigens are regulated post-tran-
scriptionally.
The protein TRAG, which is a component of a type IV
secretion system (T4SS, virulence associated pathway of
SS2), was identified. The T4SS mediates horizontal gene
transfer, thus contributing to genome plasticity, the evolu-
tion of infectious pathogens, and the dissemination of
antibiotic resistance and other virulence traits [31]. The
gene  trag  was found in 98HAH33, 05HAH33, Canada
strain 89/1591, and all the tested Chinese SS2 virulent
strains, but not in European strain P1/7 or the non-viru-
lent strain T15 (data not shown). Brucella species require
a T4SS to reach their proper niche and to replicate within
host cells [32]. Whether DNA transfer through a T4SS
occurs between SS2 isolates and results in an increase in
virulence is unknown, and will only be answered by
future studies.
Lipoproteins that are upregulated in vivo in other patho-
genic organisms have been identified, and have been
shown to be likely important for pathogenesis [33,34].
For instance, in a previous study of Vibrio vulnificus using
IVIAT, a putative lipoprotein was also found to be induced
in vivo when convalescent-phase sera from patients who
survived V. vulnificus septicemia were used to screen a
genomic library of this organism [35]. As for nlpa, almost
nothing is known about the homolog of this gene in the
NCBI database. The partial NLPA protein sequence was
identified as a lipoprotein in the 89/1591 genome data-
base, and shares 100% identity with a putative NLPA.
Others ss-154 3-phosphoglycerate kinase, phosphoglycerate 
kinase activity/glycolysis
Cytoplasmic EF127702
ss-485 Metal-dependent phosphohydrolase, HD 
subdomain/HD/PDEase superfamily
Cytoplasmic EF127730
ss-1478 Inorganic diphosphatase, Cytoplasmic EF127734
smc SMC protein, N-terminal: Structural maintenance 
of chromosome protein SMC, C-terminal: SMCs 
flexible hinge
Cytoplasmic EF127743
Function unknown g19 unknown EF127696
g59 Protein of unknown function DUF150 Cytoplasmic EF127717
g77 unknown EF127724
g78 unknown EF127725
g98 hypothetical protein Franean1DRAFT_0529 EF127732
g130 unknown EF127744
g132 unknown EF127745
† Putative functions of hypothetical proteins were determined from NCBI database and CBS Prediction Servers when available.
‡ Predicted by the PSORTb v.2.0 program.
Table 2: Proteins encoded by IVIAT selected clones (Continued)BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Figure 3 (see legend on next page)BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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In vivo gene expression at 12 h (A), 24 h (B), and 36 h (C) relative to the highest level of expression in vitro by real-time PCR  analysis Figure 3 (see previous page)
In vivo gene expression at 12 h (A), 24 h (B), and 36 h (C) relative to the highest level of expression in vitro by 
real-time PCR analysis. Total bacterial RNA extracted from strain ZY05719 grown in LB broth media was used as the tem-
plate to assay the in vitro expression levels of the 10 newly identified genes. SPF minipigs were employed as model to study the 
in vivo expression levels. Pigs were inoculated intravenously with strain ZY05719, and bacterial cells recovered from blood at 
12 h, 24 h, and 36 h post-inoculation were considered as in vivo growth bacteria. Total bacterial RNAs extracted from in vivo 
growth bacterial cells were further analyzed by real-time PCR. To determine whether RNA expression level is induced or 
upregulated under in vivo conditions, we compared in vivo gene expression with the highest level of expression in vitro. The 
standard deviations are presented from three pigs each, blood collected at 12, 24 and 48 h. 1, ss-1616; 2, trag; 3, nlpa; 4, srt; 5, 
cwh; 6, hprk; 7, ysirk; 8, ss-1955; 9, sdh; 10, ss-1298; gapdh was used as reference gene.
Graphical representation of the locations of five IVI genes on the pathogenicity islands of S. suis serotype 2 strain P1/7 Figure 4
Graphical representation of the locations of five IVI genes on the pathogenicity islands of S. suis serotype 2 
strain P1/7. Based on a complete analysis of the SS2 reference strain P1/7 genomic sequence, W. Wei et al. predicted eight 
putative pathogenicity islands (PAIs). When we determined the locations of the 48 IVI genes identified by IVIAT, we found five 
IVI genes (sdh, ss-1955, srt, ss-1829, and ss-802) located in four pathogenicity islands in SS2 reference strain P1/7. The genomic 
map was published by W. Wei et al., 2006 (gray bars the third ring represent eight possible pathogenicity islands).BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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HPr kinase/P-Ser-HPr phosphatase (HprK/P) is a phos-
phocarrier protein of the phosphoenolpyruvate: carbohy-
drate phosphotransferase system (PTS). It is also a sensor
of two-component signal transduction systems (TCSs)
[36]. Thus, HprK/P provides a link between carbon
metabolism and the development of virulence [37]. For
example, the expression of several virulence genes, such as
the hemolysin-encoding hly  and the phospholipase-
encoding plcA, is repressed when Listeria monocytogenes is
grown on cellobiose, glucose, fructose, or other rapidly
metabolizable carbon sources [38].
L-Serine dehydratase, an iron-sulfur protein [39], was
identified, and this gene was also found in the Canadian
strain 89/1591. During the course of the infection, alter-
native carbon sources (such as amino acids) are utilized
by bacteria for growth due to competition for nutrients.
The results of Velayudhan et al. showed that the catabo-
lism of L-serine by serine dehydratase was crucial for the
growth of Campylobacter jejuni under in vivo conditions
[40]. In addition, the fermentation of amino acids pro-
duces ammonia that neutralizes the surrounding pH; this
neutralization is beneficial since it protects group A Strep-
tococcus (GAS) from acid-induced damage [41].
The protein encoded by ss-1298  is an ABC-type trans-
porter, but its function is still unknown. Gene ss-1616 is a
conserved hypothetical outer membrane protein in SS2
genome database, and almost nothing is known about
this gene. It was found in all tested strains in this study,
and in Canada strain 89/1591 and European strain P1/7.
Many surface proteins of pathogenic gram-positive bacte-
ria are linked to the cell wall envelope by a sorting mech-
anism that recognizes an LPXTG motif, but surface
proteins of Streptococcus pneumoniae harbor another motif,
YSIRK-G/S [42]. About 20 surface proteins of Staphylococ-
cus aureus carry the YSIRK-G/S motif, whereas those of Lis-
teria monocytogenes and Bacillus anthracis do not [43,44].
While the function of the YSIRK motif has not been com-
pletely elucidated, it may contribute to the efficient secre-
tion of a protein [43]. In the present study, four clones
encoded two proteins containing this motif. Although the
gene ysirk was only detected 12 h after SS2 infection and
then disappeared, and was not strongly upregulated in
vivo, the mature protein encoded by ysirk1 showed homol-
ogy to the surface-associated subtilisin-like serine protease
PrtA (a virulence factor) of S. pneumoniae[21]. However,
the role of this protein during SS2 infection remains to be
determined.
IVIAT enables the identification both of proteins
expressed specifically during host infection but not during
growth under standard laboratory conditions, and of pro-
teins expressed at significantly higher levels in vivo than in
vitro. But IVIAT has its own limitations. IVIAT will not
identify all virulence-associated genes. Genes that are
expressed both in vivo and in vitro and genes that are not
expressed effectively in the E. coli host expression system
will not be identified. For instance, some previously
reported SS2 virulence factors, such as MRP, EF, FBPs,
CPS, and SLY, could not be screened out by IVIAT in this
study. We speculate that they are expressed in both in vivo
and in vitro growth conditions, and therefore antibodies
specific to these antigens had been eliminated during the
convalescent sera adsorption steps.
Unexpectedly, some of the genes identified are likely
expressed during in vitro growth conditions, such as DNA
polymerase I and III, Primosomal protein n, protein
Cpn60, and SMC protein (essential for bacterial cell divi-
sion and cell wall biosynthesis). We speculate that per-
haps their expression level was higher during in vivo
growth than in vitro growth, and therefore they were
detected by the IVIAT.
Table 3: Distributions of 10 IVI genes in SS2 strains
strain serotype host region year Gene Name
1234567891 0
HA9801* 2 Pig China 1998 + + + + + + + + + +
ZY05719* 2 Pig China 2005 + + + + + + + + + +
89/1591‡ 2 N C a n a d a N +++++++++ +
P1/7‡ 2 N N N +++++-+++ +
05ZYH33‡ 2 h u m a n C h i n a 2 0 0 5 +++++++++ +
98HAH33‡ 2 h u m a n C h i n a 1 9 9 8 +++++++++ +
*, The distribution of the 10 IVI genes in strains was analyzed by colony PCR.
‡, The distribution of the 10 IVI genes in strains was performed through alignment the IVI genes with corresponding genomic sequence.
, 1, cwh; 2, hprk; 3, ysirk; 4, ss-1616; 5, ss-1955; 6, trag; 7, sdh; 8, srt; 9, ss-1298; 10, nlpa.
N, Background not reported in related publication.
+, positive or found in the related genome sequence.
-, negative or not found in the related genome sequence.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Conclusion
Taken together, our results suggest that during the course
of infection, bacterial metabolism, envelope composi-
tion, and virulence will be adjusted for bacteria to survive
in the hostile environment. Bacterial pathogens sense
their environment, and in response, genes are induced or
repressed through spatial and temporal regulation. Genes
and gene pathways identified by IVIAT may play a role in
virulence or pathogenesis during host infection, and may
be appropriate for inclusion in therapeutic, vaccine, or
diagnostic applications. The results of this study yielded a
set of potentially valuable proteins of a manageable
number for future studies on SS2 pathogenicity and for
the development of specific diagnostics and vaccines.
Methods
Bacterial strains and plasmids
The bacterial strains and plasmids used in this study are
listed in Table 1. The S. suis strains were grown in Todd-
Hewitt broth (THB) (Oxoid) or Todd-Hewitt agar (THA)
(Oxoid) plates supplemented with 2% inactivated calf
serum. Strain ZY05719 was originally isolated from the
2005 Sichuan SS2 infection outbreak in China. E. coli
DH5α was used as the host strain for cloning, and E. coli
BL21 (DE3) was used as the host strain for the recom-
binant proteins. The E. coli strains were grown in Luria-
Bertani (LB) media and stored at -40°C in LB broth con-
taining 20% glycerol. Plasmid-transformed E. coli cells
were grown in LB medium supplemented with 30 μg/mL
kanamycin (kan).
DNA manipulation and strain construction
DNA manipulations were performed according to stand-
ard procedures [45]. All restriction enzymes, DNA
polymerases, ligase, and oligonucleotide primers were
purchased from TaKaRa. The mrp, ef, and gapdh genes were
amplified by PCR, and each gene was separately ligated
into pET expression vectors to construct 3 recombinant
expression plasmids (Table 1). These recombinant expres-
sion plasmids were separately introduced into E. coli BL21
(DE3) and induced to overexpress recombinant proteins.
Indirect ELISA and dot-ELISA
An indirect enzyme-linked immunosorbent assay (ELISA)
was used for screening the swine sera with the in vitro-
derived SS2 antigens. In brief, microtiter plates (Costar)
were coated with SS2 antigen (whole cells and cell
lysates). Following incubation and blocking, 100-μL dilu-
tions (1:200-1:51,200, V/V) of sera were added to the
wells. The subsequent ELISA protocol was performed as
previously described [46]. 3,3',5,5'-tetramethylbenzidine
(TMB, Amresco) was used as the substrate, and the optical
density at 450 nm (OD450) was determined with an ELISA
reader (BIO-RAD550). The antibody titer was defined as
the highest serial dilution of serum for which the OD450
value was two standard deviations above the mean OD450
of the negative controls (without primary antibody).
To assay for antibodies specific to MRP, EF, and GAPDH,
successively diluted nickel affinity-purified recombinant-
expressed MRP, EF, and GAPDH proteins were spotted on
a nitrocellulose (NC) membrane (Millipore). Dot-ELISA
was performed according to the standard procedure with
minor modifications [46]. The reactions were developed
with 3,3'-diaminobenzidine (DAB, Amresco) solution
with 0.1% H2O2.
Swine convalescent sera and control sera
Recently, a specific pathogen-free (SPF) piglet has been
developed as an animal model for studying S. suis [47,47].
Animal experiments were performed as previously
reported with minor modifications [48]. All animal exper-
iments were conducted in accordance with national
guidelines and were approved by the office of laboratory
animal, Shanghai Jiao Tong University and Shanghai
administration committee of laboratory animals.
Convalescent sera
To prevent any contact with infectious agents, SPF Bama
minipigs and healthy piglets were housed in independent
units with absolute filters. Prior to challenge, all the pigs
were negative for SS2-specific antibodies, as determined
by an ELISA test. SPF minipigs (n = 8, Guizhou line, 7
weeks old) were randomly grouped into 2 units (4/unit,
named as group 1 and 2) and piglets (n = 12, 8 weeks old)
into 2 units (6/unit, named as group 3 and 4). Bacterial
suspensions in THB with 10% inactivated bovine serum
were prepared and adjusted to a concentration of 1 × 108
colony forming units (CFU)/mL of S. suis. These pigs were
challenged with 2 mL of strain ZY05719 (1 × 108CFU/
mL), intramuscularly (i.v.) for group 1 and 3, and intrave-
nously (i.m.) for group 2 and 4, respectively. The pigs
were monitored daily post-inoculation (pi) for clinical
signs, notably fever and central nervous system dysfunc-
tions such as opisthotonos, tremors, and nystagmus. The
rectal temperature was recorded daily. No inflammation
was observed at the injection sites. Intramuscularly chal-
lenged pigs died naturally between 4 and 8 days after
experimental infection, while intravenously challenged
pigs died between 2 and 7 days. The pigs, 3 minipigs (1 for
i.v. group and 2 for i.m.) and 5 piglets (2 for i.v. group and
3 for i.m.), that recovered after being challenged were
used in the subsequent experiments performed in this
study. The antibody titer against a homologous strain was
determined by indirect ELISA every week after challenge.
At week 4, the animals were sacrificed and bled. The sera
were collected and kept frozen at -40°C. The flowchart of
piglet infections was as shown in Additional File 1: Figure
S1. Convalescent sera collected from the recovered pigs
were used for IVIAT selection.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Positive control sera
SS2-positive sera were prepared from 3 SPF minipigs
immunized with inactivated ZY05719 whole cell bacteria
(2 mL of 1 × 108 CFU each) 4 times at 2-week intervals.
Ten days after the last injection, the antisera were pooled
and used as the positive control in ELISA tests.
Negative control sera
To reduce variability animal to animal, serum samples
were obtained from healthy SPF minipigs prior to SS2
infection, negative in ELISA test, used as the negative con-
trol for IVIAT or ELISA.
Adsorption of swine convalescent-phase and control sera
To compensate for variations in the immune responses of
individual pigs, equal volumes of convalescent sera from
3 minipigs and 5 piglets were pooled and extensively
adsorbed with in vitro-derived SS2 antigens to completely
remove all antibodies that recognize the antigens that are
expressed under the in vitro condition.
The adsorption protocol has been described previously
[20]. Briefly, a Protease Inhibitor Cocktail Set II (Merck)
formulated for bacterial cells and containing 4-(2-ami-
noethyl) benzenesulfonyl fluoride (AEBSF; 20 mM),
EDTA (85 mM), bestatin (1.7 mM), pepstatin A (2 mM),
and E-64 (0.2 mM) was prepared per the manufacturer's
instructions and then added to intact cells and cell lysates
at a dilution of 1:10 (V/V). The successive adsorption
steps were performed six times with whole bacterial cells,
three with native cell lysates, and one with heat-denatured
ZY05719 cell lysates and E. coli BL21(DE3) that contain
unmodified pET-30abc expression plasmids (Novagen),
as described[15,20]. Cell lysates were prepared by sonica-
tion, and the protein concentration determined by using
spectrophotometer (Smartspec™, BIO-RAD). The cell
lysates were first coated onto nitrocellulose membranes
and the corresponding antibodies adsorbed to remove
antigen-antibody complexes. The resultant adsorbed
serum was divided into aliquots that were stored at -40°C.
To check the efficacy of each adsorption step, a 10-μL
serum aliquot was removed after each adsorption and
analyzed with ELISA against either whole SS2 cells or SS2
cell lysates.
Construction of a genomic expression library of the SS2 
strain ZY05719
An expression library was constructed with the pET-30abc
series of expression vectors, which permit the cloning of
inserts into each of the three reading frames under the
transcriptional control of the T7 phage promoter. Each
vector DNA was digested with BamHI, subjected to agar-
ose gel electrophoresis, purified by using a gel extraction
kit (TaKaRa), and treated with shrimp alkaline phos-
phatase (TaKaRa). Genomic DNA from strain ZY05719
was extracted and partially digested with Sau3AI. Next, we
ligated each of the three vectors separately with genomic
DNA fragments to create three expression libraries. These
libraries were electroporated into competent E. coli DH5α
as described previously [18,20]. We assessed the resulting
libraries by subjecting a random sample to PCR in order
to determine the frequency and size of the inserts. More
than 98% of transformants contained inserts of sizes rang-
ing from 0.1 to 4 kbp.
Screening the antigens identified by IVIAT against swine 
convalescent-phase sera
Immunoscreening was performed according to the proce-
dure described by Sambrook et al. [45]. In short, an aliq-
uot of the library with E. coli BL21 (DE3) as the expression
host was diluted and spread on sterile NC membranes
that were overlaid on kan/LB plates. After overnight incu-
bation at 37°C, the colonies were lifted onto new sterile
NC membranes, and after a 5-h incubation at 37°C, these
membranes with the lifted colonies (colony side up) were
overlaid on fresh kan/LB plates containing 1 mM isopro-
pyl-D-thiogalactopyranoside (IPTG, Amresco) and incu-
bated overnight at 37°C to induce gene expression of the
cloned inserts. The plates were exposed to chloroform
vapors for 15 min for partial bacterial lysis and for the
release of the induced proteins. Each membrane was
removed, blocked with 5% skim milk, and reacted with a
1:100 (V/V) dilution of the pooled adsorbed convales-
cent-phase sera at room temperature. The clones that
reacted with the antibodies in the adsorbed sera were
detected by using peroxidase-conjugated staphylococcal
protein A (SPA) and visualized with an Enhanced chemi-
luminescence (ECL) kit (Pierce). The immunoreactive
clones were identified by their position on the master
membrane. Each positive clone was purified at least two
additional times and confirmed as immunoreactive to the
adsorbed sera [18,20]. Plasmids from individual positive
reactive clones were purified, and the DNA inserts were
sequenced in both directions by using pET30-specific
primers.
Bioinformatic analysis
Analysis of sequence homologies, protein families, and
conserved domains was performed using NCBI BLAST
http://blast.ncbi.nlm.nih.gov, information from the
Sanger Genome Centre http://www.sanger.ac.uk/Projects/
S_suis, and PFAM http://pfam.sanger.ac.uk. The putative
functions of the newly discovered proteins were assigned
using the CBS Prediction Servers http://www.cbs.dtu.dk/
services/ProtFun. The cellular localizations of these pro-
teins were predicted using PSORTb v2.0 http://
www.psort.org/psortb/.BMC Microbiology 2009, 9:201 http://www.biomedcentral.com/1471-2180/9/201
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Real-time PCR analysis
Gene expression was tested by subjecting the RNA of the
bacteria grown under standard laboratory conditions to
real-time PCR, and the results were compared to those
obtained for bacteria recovered from infected pigs.
In vitro culture
Duplicate cultures of ZY05719 grown under in vitro con-
ditions were harvested at OD600s of 0.1, 0.2, 0.4, 0.6, and
0.8. OD600s in the ranges of 0.1-0.2, 0.2-0.6, and 0.6-0.8
correspond to the lag phase, log phase, and stationary
phase, respectively. The bacterial pellet was snap frozen in
liquid nitrogen and stored at -80°C.
In vivo gene expression
Three SPF Bama minipigs were inoculated intravenously
with ZY05719 for analyzing gene expression under in vivo
conditions. The bacterial cells were separated from blood
by centrifuging at different speeds. Blood samples were
pooled at 12, 24, and 36 h pi, centrifuged at 2,000 rpm to
remove blood cells, and repelleted at 12,000 rpm to col-
lect bacterial cell pellets that were subsequently snap fro-
zen in liquid nitrogen and stored at -80°C.
Real-time PCR
Bacterial total RNA was extracted using RNAprep Bacteria
Kit (TIANGEN, China), and residual genomic DNA was
removed by using a QIAGEN RNase-Free DNase Set (Qia-
gen) according to the manufacturer's instructions. DNase-
treated RNA samples were reverse transcribed by using a
first-strand cDNA synthesis kit (TaKaRa) according to the
manufacturer's recommendations. The controls for cDNA
synthesis and DNase treatment included two negative
controls: one with no RNA template and one without
reverse transcriptase.
Quantitative real-time PCR (qPCR) assays were per-
formed by using a Chromo4 system (BIO-RAD) and a
SYBR-Green PCR kit (Takara). All qPCR reactions were
performed in a final volume of 25 μL containing 12.5 μL
Premix Ex Taq mix (2×), 0.5 μL (10 μM) of each primer, 2
μL cDNA, and 9.5 μL double-distilled water (ddH2O). The
protocol followed for each qPCR was as follows: hot start
at 95°C for 10 s, followed by 45 cycles at 95°C for 5 s,
60°C for 20 s. Data were collected and analyzed using
Opticon Monitor software V3.1 (BIO-RAD). To normalize
the data, primer pairs were designed to amplify the gene
glyceraldehyde-3-phosphate dehydrogenase (gapdh) as
housekeeping control. Based on the gene classification, 10
genes were selected for the PCR amplification and the spe-
cific primer sets that were used are listed in Table 4. The
specificity of each resulting amplicon was validated with
its corresponding melting curve. The relative level of
expression was calculated by comparing the difference in
the threshold cycle number of the gene of interest gene
with that of the reference gene.
Colony PCR analysis
To learn about gene distribution in diverse SS2 isolates
with different backgrounds, colony PCR was used. The
primers used to detect the 10 IVI genes were same as the
oligonucleotides for qPCR (Table 4). Single SS2 colonies
Table 4: Primers used for real-time PCR in this study
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were picked from THA plates, suspended in 50 μL of
ddH2O and boiled for 10 min to make DNA lysates. Each
was assayed using the appropriate primer sets by PCR.
PCR reactions were carried out using Taq polymerase
according to the manufacturer's recommendation
(TaKaRa).
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